Entia Biosciences, Inc. (ERGO) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Entia Biosciences, Inc. (ERGO) trades at $0.0002 with AI Score 51/100 (Grade B). Entia Biosciences, Inc. (ERGO) is a biotechnology company focused on developing dietary supplements and medical foods. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for ERGO: ERGO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ERGO against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
ERGO: 2/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Entia Biosciences, Inc. (ERGO) Healthcare & Pipeline Overview
Entia Biosciences, Inc. is a biotechnology firm dedicated to the development and distribution of innovative dietary supplements and medical foods, leveraging unique formulations to address chronic health conditions and enhance well-being.
What Is the Investment Thesis for ERGO?
Entia Biosciences, Inc. presents a unique investment thesis driven by its innovative product portfolio and strategic focus on health and wellness. The company’s gross margin stands at 65.5%, indicating strong pricing power and operational efficiency. With ongoing development of products targeting chronic kidney disease, Entia is positioned to capture a growing market segment. The global dietary supplements market is projected to reach approximately $230 billion by 2027, providing a substantial growth opportunity for Entia. The company’s focus on e-commerce and direct-to-consumer sales enhances its market reach and customer engagement, potentially driving revenue growth in the coming years. However, the company must navigate its negative profit margin of -554.7% and address operational challenges to achieve sustainable profitability.
Based on FMP financials and quantitative analysis
ERGO Key Highlights
Gross margin of 65.5% indicates strong operational efficiency compared to industry averages.
- Market cap currently stands at $0.00B, reflecting its early-stage development status.
- Negative profit margin of -554.7% highlights the need for improved cost management.
- The company employs a lean workforce of 6, allowing for agile decision-making.
- Beta of 38.17 suggests high volatility, which may appeal to risk-tolerant investors.
Who Are ERGO's Competitors?
ERGO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NTRB Nutriband Inc. | $3.81 | +7.46% | $46.4M | — |
| VYGR Voyager Therapeutics, Inc. | $3.32 | -2.64% | $201M | — |
| AMRN Amarin Corporation plc | $14.06 | -2.23% | $291M | 51 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ERGO's Key Strengths?
Innovative product formulations with potential health benefits.
- Strong gross margins indicating operational efficiency.
- Direct-to-consumer sales model enhancing customer engagement.
What Are ERGO's Weaknesses?
High volatility reflected in the beta of 38.17.
- Negative profit margin indicating operational challenges.
- Limited workforce may restrict growth capabilities.
What Could Drive ERGO Stock Higher?
Launch of new products targeting chronic kidney disease.
- Development of e-commerce strategies to enhance market reach.
- Expansion of the GROH brand into new cosmeceutical markets.
What Are the Key Risks for ERGO?
Regulatory hurdles in product approvals could delay market entry.
- High operational costs leading to negative profit margins.
- Market competition may impact pricing and sales strategies.
What Are the Growth Opportunities for ERGO?
- Product Development in Chronic Kidney Disease: Entia is developing specialized products targeting chronic kidney disease, a condition affecting millions globally. The market for renal care products is projected to grow significantly, driven by increasing prevalence and awareness. By 2027, the global renal care market is expected to reach $30 billion, presenting a substantial opportunity for Entia to capture market share with its innovative solutions.
- Expansion of E-commerce Channels: With the rise of online shopping, Entia's focus on e-commerce sales positions it to capitalize on this trend. The global e-commerce market for health and wellness products is expected to grow at a CAGR of 10.5% through 2025. By enhancing its digital marketing strategies and expanding its online presence, Entia can reach a broader consumer base and drive sales growth.
- Innovation in Nutraceuticals: The increasing consumer demand for natural and organic products presents an opportunity for Entia to expand its product lines. By leveraging its expertise in natural formulations, Entia can develop new products that meet consumer preferences for health and wellness.
- Strategic Partnerships: Collaborating with healthcare providers and research institutions can enhance Entia's credibility and market reach. Strategic partnerships can facilitate the development of new products and enhance distribution capabilities, allowing the company to penetrate new markets and customer segments effectively.
- Cosmeceuticals Market Entry: Entia's GROH brand offers potential for growth in the cosmeceuticals sector, which is projected to grow at a CAGR of 8.4% through 2026. By expanding its product offerings in this space, Entia can tap into the lucrative beauty and skincare market, appealing to health-conscious consumers seeking effective solutions.
What Threats Does ERGO Face?
- Intense competition in the biotechnology and nutraceutical sectors.
- Regulatory challenges related to product approvals.
- Market volatility affecting consumer spending on health products.
What Are ERGO's Competitive Advantages?
- Unique formulations backed by scientific research.
- Strong focus on e-commerce providing direct consumer access.
- Niche market positioning in dietary supplements and medical foods.
- Small team allows for agile decision-making and innovation.
What Does ERGO Do?
Entia Biosciences, Inc. was founded in 2007 and is headquartered in Sherwood, Oregon. Originally known as Total Nutraceutical Solutions, Inc., the company rebranded in January 2012 to reflect its focus on biosciences. Entia specializes in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods. Its portfolio includes proprietary formulations such as ErgoD2, a pharmaceutical-grade organic compound derived from whole foods, which is rich in micro-nutrients. The company also offers L-Ergothioneine, a naturally occurring amino acid recognized for its antioxidant properties, alongside vitamin D. Entia is actively developing products aimed at chronic kidney disease and other health conditions, as well as cosmeceuticals marketed under the GROH brand. The company utilizes e-commerce channels for direct consumer sales, employing strategies such as email marketing and social media outreach to promote its products. With a small team of six employees, Entia Biosciences is positioned in a niche market, emphasizing the scientific evaluation and marketing of its innovative health solutions.
What Products and Services Does ERGO Offer?
- Develops dietary supplements and nutraceuticals for health enhancement.
- Produces medical foods targeting specific health conditions.
- Markets proprietary formulations like ErgoD2 and L-Ergothioneine.
- Offers cosmeceuticals under the GROH brand for beauty applications.
- Utilizes e-commerce channels for direct-to-consumer sales.
- Engages in scientific evaluation and marketing of natural health products.
How Does ERGO Make Money?
- Generates revenue through the sale of dietary supplements and medical foods.
- Utilizes e-commerce platforms to reach consumers directly.
- Employs digital marketing strategies for product promotion.
- Focuses on innovative product development to meet market demands.
What Industry Does ERGO Operate In?
The biotechnology industry is experiencing significant growth, driven by increasing health awareness and demand for innovative health solutions. The global dietary supplements market is expected to grow at a CAGR of 8.2%, reaching $230 billion by 2027. Entia Biosciences, Inc. operates in a competitive landscape with various players focusing on nutraceuticals and medical foods. The company's unique formulations and emphasis on scientific evaluation provide a competitive edge in a market characterized by rapid innovation and evolving consumer preferences.
Who Are ERGO's Key Customers?
- Health-conscious consumers seeking dietary supplements.
- Patients with chronic conditions requiring specialized medical foods.
- Beauty enthusiasts interested in cosmeceuticals.
- E-commerce shoppers looking for convenient health solutions.
Key Financial Metrics
Return on equity for Entia Biosciences, Inc. stands at 106.8%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.11 means current liabilities exceed short-term assets, a liquidity point worth watching.
Entia Biosciences, Inc. (ERGO) Valuation Context
Relative to its peer group, ERGO's quantitative score of 51/100 is below the peer average of 68/100.
Company Profile
Entia Biosciences, Inc. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Sherwood, US. The company is led by CEO Timothy A. Timmins. ERGO has traded publicly since 2008.
Financial Health
Entia Biosciences, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
ERGO Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Innovative product formulations with potential health benefits.
- Strong gross margins indicating operational efficiency.
- Direct-to-consumer sales model enhancing customer engagement.
- Upcoming: Launch of new products targeting chronic kidney disease.
Bear Case
- High volatility reflected in the beta of 38.17.
- Negative profit margin indicating operational challenges.
- Limited workforce may restrict growth capabilities.
- Potential: Regulatory hurdles in product approvals could delay market entry.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
ERGO Latest News
No recent news available for ERGO.
ERGO Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ERGO.
Price Targets
Wall Street price target analysis for ERGO.
ERGO MoonshotScore
What does this score mean?
The MoonshotScore rates ERGO 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Timothy A. Timmins
CEO
Timothy A. Timmins has extensive experience in the healthcare and biotechnology sectors. He has been instrumental in guiding the strategic direction of Entia Biosciences since its inception in 2007. Timmins holds a degree in business administration and has a background in product development and marketing within the health and wellness industry.
Track Record: Under Timmins' leadership, Entia has successfully transitioned from Total Nutraceutical Solutions to a focused biotechnology firm. He has overseen the development of key product lines and the establishment of e-commerce sales channels, positioning the company for future growth.
ERGO OTC Market Information
The OTC Other tier includes companies that do not meet the requirements for higher tiers like OTCQX or OTCQB. This tier typically has less stringent reporting requirements and may have lower visibility among investors compared to NASDAQ or NYSE-listed companies.
- OTC Tier: OTC Other
- Limited financial disclosure may hinder transparency.
- Potential for low trading volume affecting liquidity.
- Higher volatility associated with OTC stocks.
- Verify the company's product pipeline and development status.
- Assess the management team's experience and track record.
- Review any available financial statements or reports.
- Investigate regulatory compliance and approval processes.
- Evaluate market trends and competitive landscape.
- Established company history since 2007.
- Rebranding to Entia Biosciences reflects strategic focus.
- Innovative product offerings backed by scientific evaluation.
Entia Biosciences, Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for ERGO?
ERGO holds an AI Score of 51/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Entia Biosciences, Inc. (ERGO) is a biotechnology company focused on developing dietary supplements and medical foods. Based in Sherwood, Oregon, it specializes in natural formulations for various …
What does Entia Biosciences, Inc. do?
Entia Biosciences, Inc. develops and distributes dietary supplements, nutraceuticals, and medical foods. The company focuses on innovative health solutions, including proprietary formulations like ErgoD2 and L-Ergothioneine, targeting various health conditions. It also offers cosmeceuticals under the GROH brand, utilizing e-commerce channels for direct consumer sales.
What are the main risks for ERGO?
Entia Biosciences faces several risks, including regulatory hurdles that could delay product approvals and market entry. The company also contends with ongoing operational costs that contribute to its negative profit margin. Additionally, intense competition in the biotechnology sector may affect pricing strategies and overall sales performance.
How does Entia Biosciences, Inc. navigate regulatory approval processes?
Entia Biosciences, Inc. must adhere to stringent regulatory standards set by the FDA for dietary supplements and medical foods. The company engages in thorough scientific evaluation and documentation of its product formulations to ensure compliance. This proactive approach helps mitigate risks associated with regulatory delays and enhances the credibility of its offerings.
What are the key factors to evaluate for ERGO?
Entia Biosciences, Inc. (ERGO) holds an AI score of 51/100 (moderate). presents a unique investment thesis driven by its innovative product portfolio and strategic focus on health and wellness. Not financial advice.
How frequently does ERGO data refresh on this page?
ERGO's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ERGO's recent stock price performance?
Entia Biosciences, Inc. (ERGO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product formulations with potential health benefits. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ERGO overvalued or undervalued right now?
Entia Biosciences, Inc. (ERGO) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ERGO before investing?
Before investing in Entia Biosciences, Inc. (ERGO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial information available due to OTC classification.